ClinicalTrials.gg
TerminatedNCT04798027VAW00001Updated Sep 11, 2025Results posted

Study of mRNA Vaccine Formulation Against COVID-19 in Healthy Adults 18 Years of Age and Older

A Phase 1/2 interventional study of SARS-CoV-2 mRNA vaccine formulation 1 and SARS-CoV-2 mRNA vaccine formulation 2 in COVID-19, sponsored by Sanofi Pasteur, a Sanofi Company. Terminated at 21 sites in 4 countries. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-11.

Sponsored by Sanofi Pasteur, a Sanofi Company (part of Sanofi) · Phase 1/2, Interventional, and Prevention

Why this study was terminated
Sponsor's decision not to pursue further development of this product given the wide availability of authorized/approved mRNA COVID-19 vaccines

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
182
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,859 studies in COVID-19 with a site in United States — 120 open to participants now, 210 under way, 16 of them phase 3. COVID-19 · United States.

Enrollment
507th of 1,321
182 · median 91
Started
2021
with 503 others
Phase 1/2
62 of 1,859
4 open now
Registered
1,005th of 1,859
by date

Among the 1,859 studies in COVID-19 with a site in United States, this one is the 507th largest by enrollment of the 1,321 interventional ones that give a count, is one of 504 that started in 2021, is one of 62 in phase 1/2, and was the 1,005th registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Open to participants now

120 of the 1,859 studies in COVID-19 with a site in United States are open now. Recruiting first, the newest first:

115 more — sign in →

All 120 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,859 studies in COVID-19 with a site in United States, or all of them as a file.
02

Study summary

The primary objectives of the study are:

  • To describe the safety profile of all participants in each age group and each study intervention group up to 12 months post-last dose.
  • To describe the neutralizing antibody profile at Day 1, Day 22, and Day 36 of each study intervention group.

The secondary objectives of the study are:

  • To describe binding antibody profile from Day 1 to Day 387 of each study intervention group.
  • To describe the neutralizing antibody profile from Day 91 to Day 387 of each study intervention group.
  • To describe the occurrence of virologically-confirmed coronavirus disease-2019 (COVID-19)-like illness and serologically-confirmed SARS-CoV-2 infection.
  • To evaluate the correlation/association between antibody responses to SARS-CoV-2 messenger RNA (mRNA) vaccine and the risk of virologically-confirmed COVID-19-like illness and/or serologically-confirmed severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection.
Read the detailed description

The duration of each participant's participation in the study was approximately 365 days post-last injection: approximately 386 days duration for participants receiving 2 injections and approximately 365 days duration total for participants receiving a single injection.

03

Conditions studied

  • COVID-19

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged >= 18 years on the day of inclusion.
  • A female participant was eligible to participate if she was not pregnant or breastfeeding and one of the following conditions applies:
  • Was of non-. To be considered of non-childbearing potential, a female must be pre-menarche or for at least 1 year, or surgically sterile.

OR

  • Was of childbearing potential and agreed to use an effective method or abstinence from at least 4 weeks prior to the first vaccination until at least 12 weeks after the last vaccination.

A participant of childbearing potential must had a negative highly sensitive pregnancy test (urine or serum as required by local regulation) within 8 hours before the study intervention.

  • Form had been signed and dated.
  • Participant not eligible to receive, based on local guidance, or if eligible does not intend to receive an authorized/approved COVID-19 vaccine from first vaccination until completion of the key timepoint of Day 43 of follow-up of this study.

Exclusion criteria

Exclusion criteria:

  • History of COVID-19 disease or prior SARS-CoV-2 infection confirmed serologically.
  • Known or suspected congenital or acquired immunodeficiency; or receipt of therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months; or long-term systemic therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months).
  • Chronic illness or condition considered to potentially increase the risk for severe COVID illness or that, in the opinion of the Investigator, is at a stage where it might interfere with study conduct or completion.
  • Known liver disease or fatty liver.
  • Positive test for chronic active surface antigen, Hepatitis B core antibody, antibody, or (HIV) antibody from blood work collected at screening visit.
  • Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating intramuscular vaccination based on Investigator's judgment.
  • Receipt of immunoglobulins, blood or blood-derived products in the past 3 months.
  • Prior administration of a coronavirus vaccine (SARS-CoV-2, SARS-CoV, Middle East Respiratory Syndrome coronavirus [MERS-CoV]).
  • Receipt of any vaccine in the 30 days preceding the first study vaccination or planned receipt of any vaccine in the 30 days following the last study vaccination except for influenza vaccination, which might be received at least 2 weeks before and a minimum of 2 weeks after study vaccines.
  • Receipt of any therapy known to have in-vitro antiviral activity against SARS-CoV-2 within 72 hours prior to the first blood draw or planned use of such therapy 72 hours prior to study immunogenicity blood draws at Day 22 and Day 36.
  • Residence in a nursing home or long-term care facility.
  • Health care workers providing direct patient care for COVID-19 participants.

The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
182 participants (actual)

Study arms

  • Experimental
    Sentinel Cohort: SARS-CoV-2 Vaccine Ultra Low dose

    Participants received two intramuscular (IM) injections of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) Vaccine ultra-low dose on Day 1 and at Day 22, respectively.

    Biological: SARS-CoV-2 mRNA vaccine formulation 1

  • Experimental
    Sentinel Cohort: SARS-CoV-2 Vaccine Low dose

    Participants received two IM injections of SARS-CoV-2 Vaccine low dose on Day 1 and at Day 22, respectively.

    Biological: SARS-CoV-2 mRNA vaccine formulation 2

  • Experimental
    Sentinel Cohort: SARS-CoV-2 Vaccine Medium dose

    Participants received two IM injections of SARS-CoV-2 Vaccine medium dose on Day 1 and at Day 22, respectively.

    Biological: SARS-CoV-2 mRNA vaccine formulation 3

  • Experimental
    FEC Cohort 1: SARS-CoV-2 Vaccine Ultra Low dose

    Participants received a single IM injection of SARS-CoV-2 Vaccine ultra-low dose on Day 1.

    Biological: SARS-CoV-2 mRNA vaccine formulation 1

  • Experimental
    FEC Cohort 1: SARS-CoV-2 Vaccine Low dose

    Participants received a single IM injection of SARS-CoV-2 Vaccine low dose on Day 1.

    Biological: SARS-CoV-2 mRNA vaccine formulation 2

  • Placebo comparator
    FEC Cohort 1: Placebo

    Participants received a single IM injection of placebo matched to SARS-CoV-2 Vaccine on Day 1.

    Biological: Placebo (0.9% normal saline)

  • Experimental
    FEC Cohort 2: SARS-CoV-2 Vaccine Ultra Low dose

    Participants received two IM injections of SARS-CoV-2 Vaccine ultra-low dose on Day 1 and at Day 22, respectively.

    Biological: SARS-CoV-2 mRNA vaccine formulation 1

  • Experimental
    FEC Cohort 2: SARS-CoV-2 Vaccine Low dose

    Participants received two IM injections of SARS-CoV-2 Vaccine low dose on Day 1 and at Day 22, respectively.

    Biological: SARS-CoV-2 mRNA vaccine formulation 2

  • Placebo comparator
    FEC Cohort 2: Placebo

    Participants received two IM injections of placebo matched to SARS-CoV-2 Vaccine on Day 1 and at Day 22, respectively.

    Biological: Placebo (0.9% normal saline)

Interventions

  • BiologicalSARS-CoV-2 mRNA vaccine formulation 1

    Pharmaceutical form: Sterile suspension Route of administration: Intramuscular injection

  • BiologicalSARS-CoV-2 mRNA vaccine formulation 2

    Pharmaceutical form: Sterile suspension Route of administration: Intramuscular injection

  • BiologicalSARS-CoV-2 mRNA vaccine formulation 3

    Pharmaceutical form: Sterile suspension Route of administration: Intramuscular injection

  • BiologicalPlacebo (0.9% normal saline)

    Pharmaceutical form: Liquid Route of administration: Intramuscular injection

06

What researchers measure

Primary outcomes

  1. Number of Participants Reporting Immediate Unsolicited Adverse Events (AEs)

    AE: any untoward medical occurrence in clinical investigation participant administered medicinal product \& which did not have any causal relationship with the treatment. Unsolicited AE: observed AE that did not fulfill conditions prelisted in case report form (CRF) in terms of diagnosis \&/or onset window post-vaccination. All participants were observed for 30 minutes after vaccination, \& any unsolicited AEs occurred during that time were recorded as immediate unsolicited AEs in CRF. Reported AEs were presented as pre-specified in protocol. In the data table, '0' in number analyzed field denotes that no participants were available for assessment for specified Group as no one in that group received vaccination 2.

    Time frame: Within 30 minutes post any and each vaccination (Vaccination 1 [i.e., at Day 1] and 2 [i.e., at Day 22])

  2. Number of Participants With Solicited Injection Site Reactions

    Solicited reaction (SR): expected adverse reaction (sign or symptom) observed \& reported under conditions (nature \& onset) prelisted (i.e., solicited) in CRF and considered as related to product administered. Solicited injection site reactions included pain, erythema, \& swelling. Reported AEs for each arm were presented as pre-specified in study protocol. In the data table, '0' in number analyzed field denotes that no participants were available for assessment for specified Group as no one in that group received vaccination 2.

    Time frame: Within 7 days after any and each vaccination (Vaccination 1 [i.e., at Day 1] and 2 [i.e., at Day 22])

  3. Number of Participants With Solicited Systemic Reactions

    SR was an expected adverse reaction (sign or symptom) observed \& reported under conditions (nature \& onset) prelisted (i.e., solicited) in CRF \& considered as related to product administered. Solicited systemic reactions included fever, headache, malaise, myalgia, arthralgia \& chills. Reported AEs for each arm were presented as pre-specified in study protocol. In the data table, '0' in number analyzed field denotes that no participants were available for assessment for specified Group as no one in that group received vaccination 2.

    Time frame: Within 7 days after any and each vaccination (Vaccination 1 [i.e., at Day 1] and 2 [i.e., at Day 22])

  4. Number of Participants With Unsolicited Adverse Events

    An AE was any untoward medical occurrence in a clinical investigation participant administered a medicinal product and which did not have any casual relationship with the treatment. An unsolicited AE was an observed AE that did not fulfill the conditions prelisted in the CRF in terms of diagnosis and/or onset window post-vaccination. Reported AEs for each arm were presented as pre-specified in the study protocol. In the data table, '0' in number analyzed field denotes that no participants were available for assessment for specified Group as no one in that group received vaccination 2.

    Time frame: Within 21 days after any and each vaccination (Vaccination 1 [i.e., at Day 1] and 2 [i.e., at Day 22])

  5. Number of Participants Reporting Serious Adverse Events (SAEs), Adverse Event of Special Interest (AESIs) and Medically Attended Adverse Events (MAAEs)

    SAEs: any untoward medical occurrence that at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or was an important medical event. AESIs: event for which ongoing monitoring \& rapid communication by investigator to the sponsor was done. MAAE was a new onset or worsening of a condition that prompted participant or participant's parent/legally acceptable representative to seek unplanned medical advice at physician's office or emergency department. Reported AEs for each arm were presented as pre-specified in study protocol.

    Time frame: From Day 1 until 12 months post last vaccination (i.e., up to Day 366 for Cohort 1 groups and up to Day 387 for Cohort 2 groups)

  6. Number of Participants With Laboratory Test Results Based on US Food and Drug Administration (FDA) Toxicity Grading Guidance

    Laboratory tests: hemoglobin (male \& female), above \& below normal white blood cell, lymphocytes, neutrophils \& eosinophils, platelet count, creatinine \& blood urea nitrogen, hyponatremia \& hypernatremia, hyperkalemia \& hypokalemia, hyperglycemia (non-fasting), hypoproteinemia, alkaline phosphate, alanine aminotransferase, aspartate aminotransferase, bilirubin (with any increase in liver function test \[LFT\], bilirubin (normal LFT), prothrombin \& partial thromboplastin time (seconds), Urine: protein, glucose \& blood. US FDA "Toxicity Grading Scale for Healthy Adults \& Adolescent Volunteers" was used for grading; Grade 1=mild, Grade 2=moderate \& Grade 3=severe. In the data table, 'number analyzed'=participants with available data for each specified category \& '0'=none of participants were available for assessment for specified Group.

    Time frame: From Day 1 up to up to 8 days post last vaccination (i.e., up to Day 9 for Cohort 1 groups; up to Day 30 for Cohort 2 groups)

  7. Geometric Mean Titers (GMTs) of Neutralizing Antibodies Against SARS-CoV-2 Recombinant Protein Vaccine at Day 1

    GMTs of SARS-CoV-2 neutralizing antibodies (D614G variant) was measured using a neutralization assay. Titers were expressed in terms of 1/dilution. Data for this OM was planned to be collected and analyzed for combined population (FEC+ Sentinel Cohort) in which same dose-level groups in Sentinel Cohort and FEC were pooled for analysis.

    Time frame: Day 1 (pre-vaccination)

  8. Geometric Mean Titers (GMTs) of Neutralizing Antibodies Against SARS-CoV-2 Recombinant Protein Vaccine at Day 22

    GMTs of SARS-CoV-2 neutralizing antibodies (D614G variant) was measured using a neutralization assay. Titers were expressed in terms of 1/dilution.

    Time frame: Day 22 (post-vaccination)

  9. Geometric Mean Titers (GMTs) of Neutralizing Antibodies Against SARS-CoV-2 Recombinant Protein Vaccine at Day 36

    GMTs of SARS-CoV-2 neutralizing antibodies (D614G variant) was measured using a neutralization assay. Titers were expressed in terms of 1/dilution.

    Time frame: Day 36 (post-vaccination)

  10. Geometric Mean Fold-rise (GMFR) of Serum Neutralization Antibody Titers at Day 22

    SARS-CoV-2 neutralizing antibodies (D614G variant) was measured using a neutralization assay. Fold-rise was calculated as the ratio of titer values of neutralizing antibodies post-vaccination (Day 22) and pre-vaccination (on Day 1) i.e., Day 22/Day 1.

    Time frame: Day 1 (pre-vaccination) and Day 22 (post-vaccination)

  11. Geometric Mean Fold-rise of Serum Neutralization Antibody Titers at Day 36

    SARS-CoV-2 neutralizing antibodies (D614G variant) was measured using a neutralization assay. Fold-rise was calculated as the ratio of titer values of neutralizing antibodies post-vaccination (Day 36) and pre-vaccination (on Day 1) i.e., Day 36/Day 1.

    Time frame: Day 1 (pre-vaccination) and Day 36 (post-vaccination)

  12. Percentage of Participants With >=2-fold and >=4-fold Rise in Serum Neutralization Antibody Titers at Day 22

    SARS-CoV-2 neutralizing antibodies (D614G variant) was measured using a neutralization assay. The fold rise (2-fold and 4-fold) was calculated as the ratio of titer values of neutralizing antibodies post-vaccination (on Day 22) and pre-vaccination (on Day 1) i.e., Day 22/Day 1.

    Time frame: Day 1 (pre-vaccination) and Day 22 (post-vaccination)

  13. Percentage of Participants With >=2-Fold and >=4-Fold Rise in Serum Neutralization Antibody Titer at Day 36

    SARS-CoV-2 neutralizing antibodies (D614G variant) was measured using a neutralization assay. The fold rise (2-fold and 4-fold) was calculated as the ratio of titer values of neutralizing antibodies post-vaccination (on Day 36) and pre-vaccination (on Day 1) i.e., Day 36/Day 1.

    Time frame: Day 1 (pre-vaccination) and Day 36 (post-vaccination)

  14. Percentage of Participants Achieving Seroconversion Against SARS-CoV-2 Virus Antigens at Day 22

    Seroconversion was defined as participants with a Baseline (Day 1) titer values below lower limit of quantification (LLOQ) with a detectable neutralization antibody titer above assay LLOQ post injection (at Day 22). LLOQ of the neutralization assay was a titer of 10.

    Time frame: Day 22 (post-vaccination)

  15. Percentage of Participants Achieving Seroconversion Against SARS-CoV-2 Virus Antigens at Day 36

    Seroconversion was defined as participants with a Baseline (Day 1) titer values below LLOQ with a detectable neutralization antibody titer above assay LLOQ post injection (at Day 36). LLOQ of the neutralization assay was a titer of 10.

    Time frame: Day 36 (post-vaccination)

Secondary outcomes

  1. Geometric Mean Concentration (GMC) of Anti-S Binding Antibody at Day 1, 22, 36, 91, 112, 181, and 202

    GMC of Anti-S binding antibodies were assessed using enzyme-linked immunosorbent assay (ELISA) and were measured in ELISA unit/mL (ELU/mL). Data for this OM was planned to be collected and analyzed for combined population (FEC + Sentinel Cohort) in which same dose-level groups in Sentinel Cohort and FEC were pooled for analysis.

    Time frame: Day 1 (pre-vaccination); Day 22 (post-vaccination), Day 36 (post-vaccination), Day 91 (only for Cohort 1), Day 112 (only for Cohort 2), Day 181 (only for Cohort 1), and Day 202 (only for Cohort 2)

  2. Geometric Mean Fold-rise (GMFR) of Binding Antibody Concentration at Day 22, 36, 91, 112, 181, and 202

    Binding antibody titers were evaluated by ELISA. Fold-rise was calculated as the ratio of geometric mean concentrations of antibodies post-vaccination at specified timepoints and pre-vaccination (on Day 1) i.e., Day 22/Day 1, Day 36/Day 1, Day 91/Day 1, Day 112/Day 1, Day 181/Day 1, and Day 202/Day 1. Data for this OM was planned to be collected and analyzed for combined population (FEC + Sentinel Cohort) in which same dose-level groups in Sentinel Cohort and FEC were pooled for analysis.

    Time frame: Day 1 (pre-vaccination); Day 22 (post-vaccination), Day 36 (post-vaccination), Day 91 (only for Cohort 1), Day 112 (only for Cohort 2), Day 181 (only for Cohort 1), and Day 202 (only for Cohort 2)

  3. Percentage of Participants With >=2- and >=4- Fold Rise in Anti-S Binding Antibody Concentration at Day 22, 36, 91, 112, 181, and 202

    Binding antibody titers were evaluated by ELISA. Fold-rise (2-fold and 4-fold) was calculated as the ratio of geometric mean concentrations of antibodies post-vaccination at specified timepoints and pre-vaccination (on Day 1) i.e., Day 22/Day 1, Day 36/Day 1, Day 91/Day 1, Day 112/Day 1, Day 181/Day 1, and Day 202/Day 1. Data for this OM was planned to be collected and analyzed for combined population (FEC + Sentinel Cohort) in which same dose-level groups in Sentinel Cohort and FEC were pooled for analysis.

    Time frame: Day 1 (pre-vaccination); Day 22 (post-vaccination), Day 36 (post-vaccination), Day 91 (only for Cohort 1), Day 112 (only for Cohort 2), Day 181 (only for Cohort 1), and Day 202 (only for Cohort 2)

  4. Geometric Mean Titers of Neutralizing Antibody Titer Against SARS-CoV-2 Recombinant Protein Vaccine Formulations at Day 91, 112, 181, and 202

    GMTs of SARS-CoV-2 neutralizing antibodies (D614G variant) was measured using a neutralization assay. Titers were expressed in terms of 1/dilution. Data for this OM was planned to be collected and analyzed for combined population (FEC + Sentinel Cohort) in which same dose-level groups in Sentinel Cohort and FEC were pooled for analysis.

    Time frame: Cohort 1: Day 91, Day 181 and Cohort 2: Day 112, and Day 202 (post-vaccination)

  5. Geometric Mean Fold-rise of Serum Neutralization Antibody Titer at Day 91, 112, 181, and 202

    SARS-CoV-2 neutralizing antibodies (D614G variant) was measured using a neutralization assay. Fold-rise was calculated as the ratio of titer values of antibodies post-vaccination at specified timepoints and pre-vaccination (on Day 1) i.e., for Cohort 1: Day 91/Day 1, Day 181/Day 1; Cohort 2: Day 112/Day 1, and Day 202/Day 1. Data for this OM was planned to be collected and analyzed for combined population (FEC + Sentinel Cohort) in which same dose-level groups in Sentinel Cohort and FEC were pooled for analysis.

    Time frame: Day 1 (pre-vaccination), Cohort 1: Day 91, Day 181 and Cohort 2: Day 112, and Day 202 (post-vaccination)

  6. Percentage of Participants With 2-Fold and 4-Fold Rise in Serum Neutralization Antibody Titer at Day 91, 112, 181, and 202

    SARS-CoV-2 neutralizing antibodies (D614G variant) was measured using a neutralization assay. Fold-rise (2-fold and 4-fold) was calculated as the ratio of geometric mean concentrations of antibodies post-vaccination at specified timepoints and pre-vaccination (on Day 1) i.e., Day 91/Day 1, Day 112/Day 1, Day 181/Day 1, and Day 202/Day 1. Data for this OM was planned to be collected and analyzed for combined population (FEC + Sentinel Cohort) in which same dose-level groups in Sentinel Cohort and FEC were pooled for analysis.

    Time frame: Day 1 (pre-vaccination), Cohort 1: Day 91, Day 181 and Cohort 2: Day 112, and Day 202 (post-vaccination)

  7. Percentage of Participants Achieving Seroconversion Against SARS-CoV-2 Virus Antigens

    Seroconversion was defined as participants with a Baseline (Day 1) titer values below lower limit of quantification (LLOQ) with a detectable neutralization antibody titer above assay LLOQ post injection. LLOQ of the neutralization assay was a titer of 10. Data for this OM was planned to be collected and analyzed for combined population (FEC + Sentinel Cohort) in which same dose-level groups in Sentinel Cohort and FEC were pooled for analysis.

    Time frame: Cohort 1: Day 91, Day 181 and Cohort 2: Day 112, and Day 202 (post-vaccination)

  8. Number of Participants With Virologically-confirmed Coronavirus Disease (COVID-19)-Like Illness

    Virologically-confirmed COVID-19-like illness was defined by specified clinical symptoms and signs and confirmed by positive result for SARS-CoV-2 by nucleic acid amplification test (NAAT) on a respiratory sample in association with a COVID-19-like illness.

    Time frame: Cohort 1: up to Day 366 (post-vaccination) and Cohort 2: up to Day 387 (post-vaccination)

  9. Number of Participants With Serologically-confirmed SARS-CoV-2 Infection

    Serologically-confirmed SARS-CoV-2 infection as defined by SARS-CoV-2 Nucleoprotein specific antibody detection immunoassay was reported in this outcome measure.

    Time frame: Cohort 1: up to Day 366 (post-vaccination) and Cohort 2: up to Day 387 (post-vaccination)

  10. Correlates of Risk/Protection Based on Antibody Responses to SARS-CoV-2

    Correlate of risk / protection based on antibody responses to SARS-CoV-2 was evaluated using virus neutralization or ELISA, considering virologically-confirmed COVID-19-like illness and/or serologically-confirmed SARS-CoV-2 infection.

    Time frame: Cohort 1: up to Day 366 (post-vaccination) and Cohort 2: up to Day 387 (post-vaccination)

07

Results

Posted Dec 15, 2023
Limitations and caveats
Due to early termination of this study by the Sponsor prior to full enrollment, the corresponding testing was not conducted, and few planned efficacy outcome measures data were not collected and analysis was not performed.

Participant flow

The study was conducted at 17 active sites in 4 countries between 12 Mar 2021 and 27 Jun 2022. Study consisted of 2 cohorts: Sentinel Cohort and Full Enrollment Cohort (FEC). For analysis purpose, Baseline, safety and outcome measure data was planned to be collected, analyzed and reported for combined population (FEC + Sentinel Cohort) in which same dose-level groups in Sentinel Cohort and FEC were pooled for analysis.

Participant flow — Overall Study
MilestoneSentinel Cohort: SARS-CoV-2 Vaccine Ultra Low DoseSentinel Cohort: SARS-CoV-2 Vaccine Low DoseSentinel Cohort: SARS-CoV-2 Vaccine Medium DoseFEC Cohort 1: SARS-CoV-2 Vaccine Ultra Low DoseFEC Cohort 1: SARS-CoV-2 Vaccine Low DoseFEC Cohort 1: PlaceboFEC Cohort 2: SARS-CoV-2 Vaccine Ultra Low DoseFEC Cohort 2: SARS-CoV-2 Vaccine Low DoseFEC Cohort 2: Placebo
Started102510272613282914
Vaccinated on day 1102510272513282814
Vaccinated on day 2210241000019199
Safety analysis set (safas)18171036341819199
Completed000000000
Not completed102510272613282914
Withdrew: Protocol violation000010010
Withdrew: Withdrawal by subject101111322
Withdrew: Lost to follow-up130001001
Withdrew: Withdrawal by sponsor8229262411252611

Outcome measures

PrimaryNumber of Participants Reporting Immediate Unsolicited Adverse Events (AEs)

AE: any untoward medical occurrence in clinical investigation participant administered medicinal product \& which did not have any causal relationship with the treatment. Unsolicited AE: observed AE that did not fulfill conditions prelisted in case report form (CRF) in terms of diagnosis \&/or onset window post-vaccination. All participants were observed for 30 minutes after vaccination, \& any unsolicited AEs occurred during that time were recorded as immediate unsolicited AEs in CRF. Reported AEs were presented as pre-specified in protocol. In the data table, '0' in number analyzed field denotes that no participants were available for assessment for specified Group as no one in that group received vaccination 2.

Time frame:
Within 30 minutes post any and each vaccination (Vaccination 1 [i.e., at Day 1] and 2 [i.e., at Day 22])
Reported as:
Count of participants · Participants
Number of Participants Reporting Immediate Unsolicited Adverse Events (AEs)
ParticipantsCohort 1: SARS-CoV-2 Vaccine Ultra Low DoseCohort 1: SARS-CoV-2 Vaccine Low DoseCohort 1: Group 3: PlaceboCohort 2: SARS-CoV-2 Vaccine Ultra Low DoseCohort 2: SARS-CoV-2 Vaccine Low DoseCohort 2: SARS-CoV-2 Vaccine Medium DoseCohort 2: Placebo
Post Any vaccination0000000
Post vaccination 10000000
Post vaccination 2———0000
PrimaryNumber of Participants With Solicited Injection Site Reactions

Solicited reaction (SR): expected adverse reaction (sign or symptom) observed \& reported under conditions (nature \& onset) prelisted (i.e., solicited) in CRF and considered as related to product administered. Solicited injection site reactions included pain, erythema, \& swelling. Reported AEs for each arm were presented as pre-specified in study protocol. In the data table, '0' in number analyzed field denotes that no participants were available for assessment for specified Group as no one in that group received vaccination 2.

Time frame:
Within 7 days after any and each vaccination (Vaccination 1 [i.e., at Day 1] and 2 [i.e., at Day 22])
Reported as:
Count of participants · Participants
Number of Participants With Solicited Injection Site Reactions
ParticipantsCohort 1: SARS-CoV-2 Vaccine Ultra Low DoseCohort 1: SARS-CoV-2 Vaccine Low DoseCohort 1: PlaceboCohort 2: SARS-CoV-2 Vaccine Ultra Low DoseCohort 2: SARS-CoV-2 Vaccine Low DoseCohort 2: SARS-CoV-2 Vaccine Medium DoseCohort 2: Placebo
Pain Post-any vaccination282853333102
Pain Post-vaccination 1282852932101
Pain Post-vaccination 2———2832102
Erythema Post-any vaccination2004500
Erythema Post-vaccination 12003500
Erythema Post-vaccination 2———2400
Swelling Post-any vaccination1206420
Swelling Post-vaccination 11203320
Swelling Post-vaccination 2———4210
PrimaryNumber of Participants With Solicited Systemic Reactions

SR was an expected adverse reaction (sign or symptom) observed \& reported under conditions (nature \& onset) prelisted (i.e., solicited) in CRF \& considered as related to product administered. Solicited systemic reactions included fever, headache, malaise, myalgia, arthralgia \& chills. Reported AEs for each arm were presented as pre-specified in study protocol. In the data table, '0' in number analyzed field denotes that no participants were available for assessment for specified Group as no one in that group received vaccination 2.

Time frame:
Within 7 days after any and each vaccination (Vaccination 1 [i.e., at Day 1] and 2 [i.e., at Day 22])
Reported as:
Count of participants · Participants
Number of Participants With Solicited Systemic Reactions
ParticipantsCohort 1: SARS-CoV-2 Vaccine Ultra Low DoseCohort 1: SARS-CoV-2 Vaccine Low DoseCohort 1: PlaceboCohort 2: SARS-CoV-2 Vaccine Ultra Low DoseCohort 2: SARS-CoV-2 Vaccine Low DoseCohort 2: SARS-CoV-2 Vaccine Medium DoseCohort 2: Placebo
Fever Post-any vaccination581916100
Fever Post-vaccination 1581611100
Fever Post-vaccination 2———71280
Headache Post-any vaccination171762631105
Headache Post-vaccination 117176222793
Headache Post-vaccination 2———212773
Malaise Post-any vaccination212152831102
Malaise Post-vaccination 121215252892
Malaise Post-vaccination 2———222892
Myalgia Post-any vaccination20234282882
Myalgia Post-vaccination 120234232482
Myalgia Post-vaccination 2———222572
Arthralgia Post-any vaccination71322023102
Arthralgia Post-vaccination 17132111851
Arthralgia Post-vaccination 2———171972
Chills Post-any vaccination14174202991
Chills Post-vaccination 114174152380
Chills Post-vaccination 2———172571
PrimaryNumber of Participants With Unsolicited Adverse Events

An AE was any untoward medical occurrence in a clinical investigation participant administered a medicinal product and which did not have any casual relationship with the treatment. An unsolicited AE was an observed AE that did not fulfill the conditions prelisted in the CRF in terms of diagnosis and/or onset window post-vaccination. Reported AEs for each arm were presented as pre-specified in the study protocol. In the data table, '0' in number analyzed field denotes that no participants were available for assessment for specified Group as no one in that group received vaccination 2.

Time frame:
Within 21 days after any and each vaccination (Vaccination 1 [i.e., at Day 1] and 2 [i.e., at Day 22])
Reported as:
Count of participants · Participants
Number of Participants With Unsolicited Adverse Events
ParticipantsCohort 1: SARS-CoV-2 Vaccine Ultra Low DoseCohort 1: SARS-CoV-2 Vaccine Low DoseCohort 1: PlaceboCohort 2: SARS-CoV-2 Vaccine Ultra Low DoseCohort 2: SARS-CoV-2 Vaccine Low DoseCohort 2: SARS-CoV-2 Vaccine Medium DoseCohort 2: Placebo
Post Any vaccination1748101553
Post vaccination 11748101052
Post vaccination 2———51021
PrimaryNumber of Participants Reporting Serious Adverse Events (SAEs), Adverse Event of Special Interest (AESIs) and Medically Attended Adverse Events (MAAEs)

SAEs: any untoward medical occurrence that at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or was an important medical event. AESIs: event for which ongoing monitoring \& rapid communication by investigator to the sponsor was done. MAAE was a new onset or worsening of a condition that prompted participant or participant's parent/legally acceptable representative to seek unplanned medical advice at physician's office or emergency department. Reported AEs for each arm were presented as pre-specified in study protocol.

Time frame:
From Day 1 until 12 months post last vaccination (i.e., up to Day 366 for Cohort 1 groups and up to Day 387 for Cohort 2 groups)
Reported as:
Count of participants · Participants
Number of Participants Reporting Serious Adverse Events (SAEs), Adverse Event of Special Interest (AESIs) and Medically Attended Adverse Events (MAAEs)
ParticipantsCohort 1: SARS-CoV-2 Vaccine Ultra Low DoseCohort 1: SARS-CoV-2 Vaccine Low DoseCohort 1: PlaceboCohort 2: SARS-CoV-2 Vaccine Ultra Low DoseCohort 2: SARS-CoV-2 Vaccine Low DoseCohort 2: SARS-CoV-2 Vaccine Medium DoseCohort 2: Placebo
SAEs0010010
AESI3323111
MAAEs6216632
PrimaryNumber of Participants With Laboratory Test Results Based on US Food and Drug Administration (FDA) Toxicity Grading Guidance

Laboratory tests: hemoglobin (male \& female), above \& below normal white blood cell, lymphocytes, neutrophils \& eosinophils, platelet count, creatinine \& blood urea nitrogen, hyponatremia \& hypernatremia, hyperkalemia \& hypokalemia, hyperglycemia (non-fasting), hypoproteinemia, alkaline phosphate, alanine aminotransferase, aspartate aminotransferase, bilirubin (with any increase in liver function test \[LFT\], bilirubin (normal LFT), prothrombin \& partial thromboplastin time (seconds), Urine: protein, glucose \& blood. US FDA "Toxicity Grading Scale for Healthy Adults \& Adolescent Volunteers" was used for grading; Grade 1=mild, Grade 2=moderate \& Grade 3=severe. In the data table, 'number analyzed'=participants with available data for each specified category \& '0'=none of participants were available for assessment for specified Group.

Time frame:
From Day 1 up to up to 8 days post last vaccination (i.e., up to Day 9 for Cohort 1 groups; up to Day 30 for Cohort 2 groups)
Reported as:
Count of participants · Participants
Number of Participants With Laboratory Test Results Based on US Food and Drug Administration (FDA) Toxicity Grading Guidance
ParticipantsCohort 1: SARS-CoV-2 Vaccine Ultra Low DoseCohort 1: SARS-CoV-2 Vaccine Low DoseCohort 1: PlaceboCohort 2: SARS-CoV-2 Vaccine Ultra Low DoseCohort 2: SARS-CoV-2 Vaccine Low DoseCohort 2: SARS-CoV-2 Vaccine Medium DoseCohort 2: Placebo
Hemoglobin (Female): Grade 10112001
Hemoglobin (Female): Grade 20001000
Hemoglobin (Female): Grade 30000000
Hemoglobin (Male): Grade 11200110
Hemoglobin (Male): Grade 20000000
Hemoglobin (Male): Grade 30000000
Above normal white blood cell: Grade 10101000
Above normal white blood cell: Grade 20000000
Above normal white blood cell: Grade 30000000
Below normal white blood cell: Grade 11110101
Below normal white blood cell: Grade 20000000
Below normal white blood cell: Grade 30000000
Platelets Decreased: Grade 10000000
Platelets Decreased: Grade 20000000
Platelets Decreased: Grade 30000000
Absolute Neutrophils Decreased: Grade 11110600
Absolute Neutrophils Decreased: Grade 21000001
Absolute Neutrophils Decreased: Grade 30000000
Absolute Lymphocytes Decreased: Grade 11011000
Absolute Lymphocytes Decreased: Grade 20000000
Absolute Lymphocytes Decreased: Grade 30000000
Absolute Eosinophils: Grade 10002000
Absolute Eosinophils: Grade 20000000
Absolute Eosinophils: Grade 30000000
Hyponatremia: Grade 11130100
Hyponatremia: Grade 20000000
Hyponatremia: Grade 30000000
Hypernatremia: Grade 10000000
Hypernatremia: Grade 20010000
Hypernatremia: Grade 30100000
Hyperkalemia: Grade 10101000
Hyperkalemia: Grade 20000000
Hyperkalemia: Grade 30000000
Hypokalemia: Grade 10000000
Hypokalemia: Grade 20101000
Hypokalemia: Grade 30110000
Blood Urea Nitrogen: Grade 10000000
Blood Urea Nitrogen: Grade 20000000
Blood Urea Nitrogen: Grade 30000000
Creatinine: Grade 10000000
Creatinine: Grade 20000000
Creatinine: Grade 30000000
Hyperglycemia: Grade 12002300
Hyperglycemia: Grade 22001200
Hyperglycemia: Grade 30000000
Hypoproteinemia: Grade 11011000
Hypoproteinemia: Grade 20000000
Hypoproteinemia: Grade 30000000
Alanine aminotransferase: Grade 11020120
Alanine aminotransferase: Grade 20000000
Alanine aminotransferase: Grade 30000000
Aspartate aminotransferase: Grade 11020100
Aspartate aminotransferase: Grade 20000000
Aspartate aminotransferase: Grade 30000000
Alkaline phosphate: Grade 10010200
Alkaline phosphate: Grade 20000000
Alkaline phosphate: Grade 30000000
Bilirubin - with any increase in LFT: Grade 10—0—00—
Bilirubin - with any increase in LFT: Grade 20—0—00—
Bilirubin - with any increase in LFT: Grade 30—0—00—
Bilirubin - with normal in LFT: Grade 10001000
Bilirubin - with normal in LFT: Grade 20000000
Bilirubin - with normal in LFT: Grade 30000000
Prothrombin time: Grade 10203300
Prothrombin time: Grade 20001000
Prothrombin time: Grade 30000000
Partial thromboplastin time: Grade 11213200
Partial thromboplastin time: Grade 20000000
Partial thromboplastin time: Grade 30000000
Urine - glucose: Grade 10000000
Urine - glucose: Grade 20000100
Urine - glucose: Grade 31000000
Urine - protein: Grade 13521411
Urine - protein: Grade 21002000
Urine - protein: Grade 30001000
Urine - blood: Grade 10100001
Urine - blood: Grade 22001000
Urine - blood: Grade 30002010
PrimaryGeometric Mean Titers (GMTs) of Neutralizing Antibodies Against SARS-CoV-2 Recombinant Protein Vaccine at Day 1

GMTs of SARS-CoV-2 neutralizing antibodies (D614G variant) was measured using a neutralization assay. Titers were expressed in terms of 1/dilution. Data for this OM was planned to be collected and analyzed for combined population (FEC+ Sentinel Cohort) in which same dose-level groups in Sentinel Cohort and FEC were pooled for analysis.

Time frame:
Day 1 (pre-vaccination)
Reported as:
Geometric mean · titer
Geometric Mean Titers (GMTs) of Neutralizing Antibodies Against SARS-CoV-2 Recombinant Protein Vaccine at Day 1
titerCohort 1: SARS-CoV-2 Vaccine Ultra Low DoseCohort 1: SARS-CoV-2 Vaccine Low DoseCohort 1: PlaceboCohort 2: SARS-CoV-2 Vaccine Ultra Low DoseCohort 2: SARS-CoV-2 Vaccine Low DoseCohort 2: SARS-CoV-2 Vaccine Medium DoseCohort 2: Placebo
Geometric Mean Titers (GMTs) of Neutralizing Antibodies Against SARS-CoV-2 Recombinant Protein Vaccine at Day 15.00 (NA to NA)5.00 (NA to NA)5.00 (NA to NA)5.00 (NA to NA)5.00 (NA to NA)5.00 (NA to NA)5.00 (NA to NA)
PrimaryGeometric Mean Titers (GMTs) of Neutralizing Antibodies Against SARS-CoV-2 Recombinant Protein Vaccine at Day 22

GMTs of SARS-CoV-2 neutralizing antibodies (D614G variant) was measured using a neutralization assay. Titers were expressed in terms of 1/dilution.

Time frame:
Day 22 (post-vaccination)
Reported as:
Geometric mean · titer
Geometric Mean Titers (GMTs) of Neutralizing Antibodies Against SARS-CoV-2 Recombinant Protein Vaccine at Day 22
titerCohort 1: SARS-CoV-2 Vaccine Ultra Low DoseCohort 1: SARS-CoV-2 Vaccine Low DoseCohort 1: PlaceboCohort 2: SARS-CoV-2 Vaccine Ultra Low DoseCohort 2: SARS-CoV-2 Vaccine Low DoseCohort 2: SARS-CoV-2 Vaccine Medium DoseCohort 2: Placebo
Geometric Mean Titers (GMTs) of Neutralizing Antibodies Against SARS-CoV-2 Recombinant Protein Vaccine at Day 2224.0 (15.3 to 37.6)29.7 (14.8 to 59.6)6.66 (3.61 to 12.3)35.2 (21.0 to 59.0)27.7 (16.4 to 46.9)68.2 (29.0 to 160)12.8 (2.52 to 65.1)
PrimaryGeometric Mean Titers (GMTs) of Neutralizing Antibodies Against SARS-CoV-2 Recombinant Protein Vaccine at Day 36

GMTs of SARS-CoV-2 neutralizing antibodies (D614G variant) was measured using a neutralization assay. Titers were expressed in terms of 1/dilution.

Time frame:
Day 36 (post-vaccination)
Reported as:
Geometric mean · titer
Geometric Mean Titers (GMTs) of Neutralizing Antibodies Against SARS-CoV-2 Recombinant Protein Vaccine at Day 36
titerCohort 1: SARS-CoV-2 Vaccine Ultra Low DoseCohort 1: Group 2: SARS-CoV-2 Vaccine Low DoseCohort 1: PlaceboCohort 2: SARS-CoV-2 Vaccine Ultra Low DoseCohort 2: SARS-CoV-2 Vaccine Low DoseCohort 2: SARS-CoV-2 Vaccine Medium DoseCohort 2: Placebo
Geometric Mean Titers (GMTs) of Neutralizing Antibodies Against SARS-CoV-2 Recombinant Protein Vaccine at Day 3613.6 (8.88 to 20.9)30.1 (15.5 to 58.6)6.48 (3.68 to 11.4)174 (111 to 273)223 (147 to 336)416 (303 to 570)11.6 (2.43 to 55.5)
PrimaryGeometric Mean Fold-rise (GMFR) of Serum Neutralization Antibody Titers at Day 22

SARS-CoV-2 neutralizing antibodies (D614G variant) was measured using a neutralization assay. Fold-rise was calculated as the ratio of titer values of neutralizing antibodies post-vaccination (Day 22) and pre-vaccination (on Day 1) i.e., Day 22/Day 1.

Time frame:
Day 1 (pre-vaccination) and Day 22 (post-vaccination)
Reported as:
Geometric mean · ratio
Geometric Mean Fold-rise (GMFR) of Serum Neutralization Antibody Titers at Day 22
ratioCohort 1: SARS-CoV-2 Vaccine Ultra Low DoseCohort 1: SARS-CoV-2 Vaccine Low DoseCohort 1: PlaceboCohort 2: SARS-CoV-2 Vaccine Ultra Low DoseCohort 2: SARS-CoV-2 Vaccine Low DoseCohort 2: SARS-CoV-2 Vaccine Medium DoseCohort 2: Placebo
Geometric Mean Fold-rise (GMFR) of Serum Neutralization Antibody Titers at Day 224.80 (3.07 to 7.52)5.93 (2.95 to 11.9)1.36 (0.704 to 2.62)7.05 (4.21 to 11.8)5.55 (3.28 to 9.37)13.6 (5.79 to 32.1)1.32 (0.682 to 2.57)
PrimaryGeometric Mean Fold-rise of Serum Neutralization Antibody Titers at Day 36

SARS-CoV-2 neutralizing antibodies (D614G variant) was measured using a neutralization assay. Fold-rise was calculated as the ratio of titer values of neutralizing antibodies post-vaccination (Day 36) and pre-vaccination (on Day 1) i.e., Day 36/Day 1.

Time frame:
Day 1 (pre-vaccination) and Day 36 (post-vaccination)
Reported as:
Geometric mean · ratio
Geometric Mean Fold-rise of Serum Neutralization Antibody Titers at Day 36
ratioCohort 1: SARS-CoV-2 Vaccine Ultra Low DoseCohort 1: SARS-CoV-2 Vaccine Low DoseCohort 1: PlaceboCohort 2: SARS-CoV-2 Vaccine Ultra Low DoseCohort 2: SARS-CoV-2 Vaccine Low DoseCohort 2: SARS-CoV-2 Vaccine Medium DoseCohort 2: Placebo
Geometric Mean Fold-rise of Serum Neutralization Antibody Titers at Day 362.84 (1.83 to 4.40)6.03 (3.10 to 11.7)1.32 (0.714 to 2.46)34.9 (22.3 to 54.6)44.6 (29.5 to 67.3)83.1 (60.7 to 114)1.20 (0.777 to 1.86)
PrimaryPercentage of Participants With >=2-fold and >=4-fold Rise in Serum Neutralization Antibody Titers at Day 22

SARS-CoV-2 neutralizing antibodies (D614G variant) was measured using a neutralization assay. The fold rise (2-fold and 4-fold) was calculated as the ratio of titer values of neutralizing antibodies post-vaccination (on Day 22) and pre-vaccination (on Day 1) i.e., Day 22/Day 1.

Time frame:
Day 1 (pre-vaccination) and Day 22 (post-vaccination)
Reported as:
Number · percentage of participants
Percentage of Participants With >=2-fold and >=4-fold Rise in Serum Neutralization Antibody Titers at Day 22
percentage of participantsCohort 1: SARS-CoV-2 Vaccine Ultra Low DoseCohort 1: SARS-CoV-2 Vaccine Low DoseCohort 1: PlaceboCohort 2: SARS-CoV-2 Vaccine Ultra Low DoseCohort 2: SARS-CoV-2 Vaccine Low DoseCohort 2: SARS-CoV-2 Vaccine Medium DoseCohort 2: Placebo
>=2-fold rise77.4 (58.9 to 90.4)66.7 (44.7 to 84.4)6.7 (0.2 to 31.9)81.3 (63.6 to 92.8)74.2 (55.4 to 88.1)100 (69.2 to 100)12.5 (0.3 to 52.7)
>=4-fold rise58.1 (39.1 to 75.5)58.3 (36.6 to 77.9)6.7 (0.2 to 31.9)71.9 (53.3 to 86.3)54.8 (36.0 to 72.7)100 (69.2 to 100)12.5 (0.3 to 52.7)
PrimaryPercentage of Participants With >=2-Fold and >=4-Fold Rise in Serum Neutralization Antibody Titer at Day 36

SARS-CoV-2 neutralizing antibodies (D614G variant) was measured using a neutralization assay. The fold rise (2-fold and 4-fold) was calculated as the ratio of titer values of neutralizing antibodies post-vaccination (on Day 36) and pre-vaccination (on Day 1) i.e., Day 36/Day 1.

Time frame:
Day 1 (pre-vaccination) and Day 36 (post-vaccination)
Reported as:
Number · percentage of participants
Percentage of Participants With >=2-Fold and >=4-Fold Rise in Serum Neutralization Antibody Titer at Day 36
percentage of participantsCohort 1: Group 1: SARS-CoV-2 Vaccine Ultra Low DoseCohort 1: Group 2: SARS-CoV-2 Vaccine Low DoseCohort 1: Group 3: PlaceboCohort 2: Group 4: SARS-CoV-2 Vaccine Ultra Low DoseCohort 2: Group 5: SARS-CoV-2 Vaccine Low DoseCohort 2: Group 6: SARS-CoV-2 Vaccine Medium DoseCohort 2: Group 7: Placebo
>=2-fold rise58.3 (36.6 to 77.9)77.8 (52.4 to 93.6)8.3 (0.2 to 38.5)96.6 (82.2 to 99.9)100 (88.8 to 100)100 (69.2 to 100)12.5 (0.3 to 52.7)
>=4-fold rise45.8 (25.6 to 67.2)66.7 (41.0 to 86.7)8.3 (0.2 to 38.5)96.6 (82.2 to 99.9)100 (88.8 to 100)100 (69.2 to 100)12.5 (0.3 to 52.7)
PrimaryPercentage of Participants Achieving Seroconversion Against SARS-CoV-2 Virus Antigens at Day 22

Seroconversion was defined as participants with a Baseline (Day 1) titer values below lower limit of quantification (LLOQ) with a detectable neutralization antibody titer above assay LLOQ post injection (at Day 22). LLOQ of the neutralization assay was a titer of 10.

Time frame:
Day 22 (post-vaccination)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Seroconversion Against SARS-CoV-2 Virus Antigens at Day 22
percentage of participantsCohort 1: SARS-CoV-2 Vaccine Ultra Low DoseCohort 1: SARS-CoV-2 Vaccine Low DoseCohort 1: PlaceboCohort 2: SARS-CoV-2 Vaccine Ultra Low DoseCohort 2: SARS-CoV-2 Vaccine Low DoseCohort 2: SARS-CoV-2 Vaccine Medium DoseCohort 2: Placebo
Percentage of Participants Achieving Seroconversion Against SARS-CoV-2 Virus Antigens at Day 2277.4 (58.9 to 90.4)66.7 (44.7 to 84.4)6.7 (0.2 to 31.9)81.3 (63.6 to 92.8)74.2 (55.4 to 88.1)100 (69.2 to 100)12.5 (0.3 to 52.7)
PrimaryPercentage of Participants Achieving Seroconversion Against SARS-CoV-2 Virus Antigens at Day 36

Seroconversion was defined as participants with a Baseline (Day 1) titer values below LLOQ with a detectable neutralization antibody titer above assay LLOQ post injection (at Day 36). LLOQ of the neutralization assay was a titer of 10.

Time frame:
Day 36 (post-vaccination)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Seroconversion Against SARS-CoV-2 Virus Antigens at Day 36
percentage of participantsCohort 1: SARS-CoV-2 Vaccine Ultra Low DoseCohort 1: SARS-CoV-2 Vaccine Low DoseCohort 1: PlaceboCohort 2: SARS-CoV-2 Vaccine Ultra Low DoseCohort 2: SARS-CoV-2 Vaccine Low DoseCohort 2: SARS-CoV-2 Vaccine Medium DoseCohort 2: Placebo
Percentage of Participants Achieving Seroconversion Against SARS-CoV-2 Virus Antigens at Day 3658.3 (36.6 to 77.9)77.8 (52.4 to 93.6)8.3 (0.2 to 38.5)96.6 (82.2 to 99.9)100 (88.8 to 100)100 (69.2 to 100)12.5 (0.3 to 52.7)
SecondaryGeometric Mean Concentration (GMC) of Anti-S Binding Antibody at Day 1, 22, 36, 91, 112, 181, and 202

GMC of Anti-S binding antibodies were assessed using enzyme-linked immunosorbent assay (ELISA) and were measured in ELISA unit/mL (ELU/mL). Data for this OM was planned to be collected and analyzed for combined population (FEC + Sentinel Cohort) in which same dose-level groups in Sentinel Cohort and FEC were pooled for analysis.

Time frame:
Day 1 (pre-vaccination); Day 22 (post-vaccination), Day 36 (post-vaccination), Day 91 (only for Cohort 1), Day 112 (only for Cohort 2), Day 181 (only for Cohort 1), and Day 202 (only for Cohort 2)
Reported as:
Geometric mean · ELU/mL
Geometric Mean Concentration (GMC) of Anti-S Binding Antibody at Day 1, 22, 36, 91, 112, 181, and 202
ELU/mLCohort 1: SARS-CoV-2 Vaccine Ultra Low DoseCohort 1: SARS-CoV-2 Vaccine Low DoseCohort 1: PlaceboCohort 2: SARS-CoV-2 Vaccine Ultra Low DoseCohort 2: SARS-CoV-2 Vaccine Low DoseCohort 2: SARS-CoV-2 Vaccine Medium DoseCohort 2: Placebo
Day 110.8 (9.08 to 12.7)10.8 (8.84 to 13.1)9.45 (NA to NA)10.1 (8.78 to 11.7)10.5 (8.93 to 12.3)10.3 (8.52 to 12.4)14.4 (7.08 to 29.4)
Day 22239 (153 to 375)372 (192 to 723)13.2 (7.84 to 22.4)448 (249 to 805)476 (279 to 812)1618 (984 to 2660)34.5 (5.22 to 228)
Day 36188 (110 to 319)310 (165 to 582)14.1 (7.52 to 26.3)3618 (2431 to 5382)4903 (3326 to 7228)10952 (7252 to 16540)34.4 (5.31 to 223)
Day 91185 (36.4 to 936)1122 (117 to 10789)31.2 (NA to NA)————
Day 112———4548 (1090 to 18981)1435 (696 to 2962)2782 (1138 to 6799)96.3 (6.61 to 1402)
Day 18162.823251—————
Day 202———3841209 (344 to 4257)—17316
SecondaryGeometric Mean Fold-rise (GMFR) of Binding Antibody Concentration at Day 22, 36, 91, 112, 181, and 202

Binding antibody titers were evaluated by ELISA. Fold-rise was calculated as the ratio of geometric mean concentrations of antibodies post-vaccination at specified timepoints and pre-vaccination (on Day 1) i.e., Day 22/Day 1, Day 36/Day 1, Day 91/Day 1, Day 112/Day 1, Day 181/Day 1, and Day 202/Day 1. Data for this OM was planned to be collected and analyzed for combined population (FEC + Sentinel Cohort) in which same dose-level groups in Sentinel Cohort and FEC were pooled for analysis.

Time frame:
Day 1 (pre-vaccination); Day 22 (post-vaccination), Day 36 (post-vaccination), Day 91 (only for Cohort 1), Day 112 (only for Cohort 2), Day 181 (only for Cohort 1), and Day 202 (only for Cohort 2)
Reported as:
Geometric mean · ratio
Geometric Mean Fold-rise (GMFR) of Binding Antibody Concentration at Day 22, 36, 91, 112, 181, and 202
ratioCohort 1: SARS-CoV-2 Vaccine Ultra Low DoseCohort 1: SARS-CoV-2 Vaccine Low DoseCohort 1: PlaceboCohort 2: SARS-CoV-2 Vaccine Ultra Low DoseCohort 2: SARS-CoV-2 Vaccine Low DoseCohort 2: SARS-CoV-2 Vaccine Medium DoseCohort 2: Placebo
Day 22/Day 122.5 (13.9 to 36.2)36.7 (17.5 to 76.9)1.28 (0.757 to 2.15)44.2 (24.4 to 80.0)45.3 (26.6 to 77.3)158 (93.7 to 265)2.39 (0.626 to 9.13)
Day 36/Day 119.5 (11.1 to 34.1)30.2 (14.6 to 62.7)1.34 (0.706 to 2.53)354 (228 to 551)466 (318 to 682)1067 (712 to 1601)2.38 (0.645 to 8.81)
Day 91/Day 126.8 (4.80 to 150)135 (9.27 to 1971)2.83 (NA to NA)————
Day 112/Day 1———481 (115 to 2009)131 (61.0 to 282)271 (110 to 670)5.40 (0.445 to 65.5)
Day 181/Day 16.652460—————
Day 202/Day 1———40.6101 (25.9 to 392)—125
SecondaryPercentage of Participants With >=2- and >=4- Fold Rise in Anti-S Binding Antibody Concentration at Day 22, 36, 91, 112, 181, and 202

Binding antibody titers were evaluated by ELISA. Fold-rise (2-fold and 4-fold) was calculated as the ratio of geometric mean concentrations of antibodies post-vaccination at specified timepoints and pre-vaccination (on Day 1) i.e., Day 22/Day 1, Day 36/Day 1, Day 91/Day 1, Day 112/Day 1, Day 181/Day 1, and Day 202/Day 1. Data for this OM was planned to be collected and analyzed for combined population (FEC + Sentinel Cohort) in which same dose-level groups in Sentinel Cohort and FEC were pooled for analysis.

Time frame:
Day 1 (pre-vaccination); Day 22 (post-vaccination), Day 36 (post-vaccination), Day 91 (only for Cohort 1), Day 112 (only for Cohort 2), Day 181 (only for Cohort 1), and Day 202 (only for Cohort 2)
Reported as:
Number · percentage of participants
Percentage of Participants With >=2- and >=4- Fold Rise in Anti-S Binding Antibody Concentration at Day 22, 36, 91, 112, 181, and 202
percentage of participantsCohort 1: SARS-CoV-2 Vaccine Ultra Low DoseCohort 1: SARS-CoV-2 Vaccine Low DoseCohort 1: PlaceboCohort 2: SARS-CoV-2 Vaccine Ultra Low DoseCohort 2: SARS-CoV-2 Vaccine Low DoseCohort 2: SARS-CoV-2 Vaccine Medium DoseCohort 2: Placebo
Day 22/Day 1: >=2-fold rise100 (88.8 to 100)100 (84.6 to 100)6.7 (0.2 to 31.9)93.8 (79.2 to 99.2)96.9 (83.8 to 99.9)100 (69.2 to 100)22.2 (2.8 to 60.0)
Day 22/Day 1: >=4-fold rise90.3 (74.2 to 98.0)86.4 (65.1 to 97.1)6.7 (0.2 to 31.9)90.6 (75.0 to 98.0)93.8 (79.2 to 99.2)100 (69.2 to 100)22.2 (2.8 to 60.0)
Day 36/Day 1: >=2-fold rise95.8 (78.9 to 99.9)100 (81.5 to 100)8.3 (0.2 to 38.5)100 (88.1 to 100)100 (88.8 to 100)100 (69.2 to 100)22.2 (2.8 to 60.0)
Day 36/Day 1: >=4-fold rise87.5 (67.6 to 97.3)88.9 (65.3 to 98.6)8.3 (0.2 to 38.5)100 (88.1 to 100)100 (88.8 to 100)100 (69.2 to 100)22.2 (2.8 to 60.0)
Day 91/Day 1: >=2-fold rise85.7 (42.1 to 99.6)100 (59.0 to 100)25.0 (0.6 to 80.6)————
Day 91/Day 1: >=4-fold rise85.7 (42.1 to 99.6)100 (59.0 to 100)25.0 (0.6 to 80.6)————
Day 112/Day 1: >=2-fold rise———100 (78.2 to 100)100 (85.2 to 100)100 (69.2 to 100)50.0 (11.8 to 88.2)
Day 112/Day 1: >=4-fold rise———100 (78.2 to 100)100 (85.2 to 100)100 (69.2 to 100)50.0 (11.8 to 88.2)
Day 181/Day 1: >=2-fold rise100 (2.5 to 100)100 (2.5 to 100)—————
Day 181/Day 1: >=4-fold rise100 (2.5 to 100)100 (2.5 to 100)—————
Day 202/Day 1: >=2-fold rise———100 (2.5 to 100)100 (76.8 to 100)—100 (2.5 to 100)
Day 202/Day 1: >=4-fold rise———100 (2.5 to 100)100 (76.8 to 100)—100 (2.5 to 100)
SecondaryGeometric Mean Titers of Neutralizing Antibody Titer Against SARS-CoV-2 Recombinant Protein Vaccine Formulations at Day 91, 112, 181, and 202

GMTs of SARS-CoV-2 neutralizing antibodies (D614G variant) was measured using a neutralization assay. Titers were expressed in terms of 1/dilution. Data for this OM was planned to be collected and analyzed for combined population (FEC + Sentinel Cohort) in which same dose-level groups in Sentinel Cohort and FEC were pooled for analysis.

Time frame:
Cohort 1: Day 91, Day 181 and Cohort 2: Day 112, and Day 202 (post-vaccination)
Reported as:
Geometric mean · titers
Geometric Mean Titers of Neutralizing Antibody Titer Against SARS-CoV-2 Recombinant Protein Vaccine Formulations at Day 91, 112, 181, and 202
titersCohort 1: SARS-CoV-2 Vaccine Ultra Low DoseCohort 1: SARS-CoV-2 Vaccine Low DoseCohort 1: PlaceboCohort 2: SARS-CoV-2 Vaccine Ultra Low DoseCohort 2: SARS-CoV-2 Vaccine Low DoseCohort 2: SARS-CoV-2 Vaccine Medium DoseCohort 2: Placebo
Day 9113.7 (6.70 to 28.1)113 (10.2 to 1263)9.33 (NA to NA)————
Day 112———322 (56.3 to 1842)69.5 (31.4 to 154)177 (52.7 to 593)23.1 (2.91 to 183)
Day 18121.02993—————
Day 202———45.0120 (25.5 to 568)—3490
SecondaryGeometric Mean Fold-rise of Serum Neutralization Antibody Titer at Day 91, 112, 181, and 202

SARS-CoV-2 neutralizing antibodies (D614G variant) was measured using a neutralization assay. Fold-rise was calculated as the ratio of titer values of antibodies post-vaccination at specified timepoints and pre-vaccination (on Day 1) i.e., for Cohort 1: Day 91/Day 1, Day 181/Day 1; Cohort 2: Day 112/Day 1, and Day 202/Day 1. Data for this OM was planned to be collected and analyzed for combined population (FEC + Sentinel Cohort) in which same dose-level groups in Sentinel Cohort and FEC were pooled for analysis.

Time frame:
Day 1 (pre-vaccination), Cohort 1: Day 91, Day 181 and Cohort 2: Day 112, and Day 202 (post-vaccination)
Reported as:
Geometric mean · ratio
Geometric Mean Fold-rise of Serum Neutralization Antibody Titer at Day 91, 112, 181, and 202
ratioCohort 1: SARS-CoV-2 Vaccine Ultra Low DoseCohort 1: SARS-CoV-2 Vaccine Low DoseCohort 1: PlaceboCohort 2: SARS-CoV-2 Vaccine Ultra Low DoseCohort 2: SARS-CoV-2 Vaccine Low DoseCohort 2: SARS-CoV-2 Vaccine Medium DoseCohort 2: Placebo
Day 91/Day 13.17 (1.49 to 6.74)22.7 (2.03 to 253)2.18 (NA to NA)————
Day 112/Day 1———64.4 (11.3 to 368)13.9 (6.28 to 30.7)35.3 (10.5 to 119)2.76 (NA to NA)
Day 181/Day 14.20599—————
Day 202/Day 1———9.0024.1 (5.09 to 114)——
SecondaryPercentage of Participants With 2-Fold and 4-Fold Rise in Serum Neutralization Antibody Titer at Day 91, 112, 181, and 202

SARS-CoV-2 neutralizing antibodies (D614G variant) was measured using a neutralization assay. Fold-rise (2-fold and 4-fold) was calculated as the ratio of geometric mean concentrations of antibodies post-vaccination at specified timepoints and pre-vaccination (on Day 1) i.e., Day 91/Day 1, Day 112/Day 1, Day 181/Day 1, and Day 202/Day 1. Data for this OM was planned to be collected and analyzed for combined population (FEC + Sentinel Cohort) in which same dose-level groups in Sentinel Cohort and FEC were pooled for analysis.

Time frame:
Day 1 (pre-vaccination), Cohort 1: Day 91, Day 181 and Cohort 2: Day 112, and Day 202 (post-vaccination)
Reported as:
Number · percentage of participants
Percentage of Participants With 2-Fold and 4-Fold Rise in Serum Neutralization Antibody Titer at Day 91, 112, 181, and 202
percentage of participantsCohort 1: SARS-CoV-2 Vaccine Ultra Low DoseCohort 1: SARS-CoV-2 Vaccine Low DoseCohort 1: Group 3: PlaceboCohort 2: SARS-CoV-2 Vaccine Ultra Low DoseCohort 2: SARS-CoV-2 Vaccine Low DoseCohort 2: SARS-CoV-2 Vaccine Medium DoseCohort 2: Placebo
Day 91/Day 1: >=2-fold rise71.4 (29.0 to 96.3)71.4 (29.0 to 96.3)25.0 (0.6 to 80.6)————
Day 91/Day 1: >=4-fold rise57.1 (18.4 to 90.1)71.4 (29.0 to 96.3)25.0 (0.6 to 80.6)————
Day 112/Day 1: >=2-fold rise———93.3 (68.1 to 99.8)90.9 (70.8 to 98.9)100 (69.2 to 100)40.0 (5.3 to 85.3)
Day 112/Day 1: >=4-fold rise———86.7 (59.5 to 98.3)77.3 (54.6 to 92.2)100 (69.2 to 100)20.0 (0.5 to 71.6)
Day 181/Day 1: >=2-fold rise100 (2.5 to 100)100 (2.5 to 100)—————
Day 181/Day 1: >=4-fold rise100 (2.5 to 100)100 (2.5 to 100)—————
Day 202/Day 1: >=2-fold rise———100 (2.5 to 100)91.7 (61.5 to 99.8)——
Day 202/Day 1: >=4-fold rise———100 (2.5 to 100)83.3 (51.6 to 97.9)——
SecondaryPercentage of Participants Achieving Seroconversion Against SARS-CoV-2 Virus Antigens

Seroconversion was defined as participants with a Baseline (Day 1) titer values below lower limit of quantification (LLOQ) with a detectable neutralization antibody titer above assay LLOQ post injection. LLOQ of the neutralization assay was a titer of 10. Data for this OM was planned to be collected and analyzed for combined population (FEC + Sentinel Cohort) in which same dose-level groups in Sentinel Cohort and FEC were pooled for analysis.

Time frame:
Cohort 1: Day 91, Day 181 and Cohort 2: Day 112, and Day 202 (post-vaccination)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Seroconversion Against SARS-CoV-2 Virus Antigens
percentage of participantsCohort 1: SARS-CoV-2 Vaccine Ultra Low DoseCohort 1: SARS-CoV-2 Vaccine Low DoseCohort 1: PlaceboCohort 2: SARS-CoV-2 Vaccine Ultra Low DoseCohort 2: SARS-CoV-2 Vaccine Low DoseCohort 2: SARS-CoV-2 Vaccine Medium DoseCohort 2: Placebo
Day 9171.4 (29.0 to 96.3)71.4 (29.0 to 96.3)25.0 (0.6 to 80.6)————
Day 112———93.3 (68.1 to 99.8)90.9 (70.8 to 98.9)100 (69.2 to 100)40.0 (5.3 to 85.3)
Day 181100 (2.5 to 100)100 (2.5 to 100)—————
Day 202———100 (2.5 to 100)91.7 (61.5 to 99.8)——
SecondaryNumber of Participants With Virologically-confirmed Coronavirus Disease (COVID-19)-Like Illness

Virologically-confirmed COVID-19-like illness was defined by specified clinical symptoms and signs and confirmed by positive result for SARS-CoV-2 by nucleic acid amplification test (NAAT) on a respiratory sample in association with a COVID-19-like illness.

Time frame:
Cohort 1: up to Day 366 (post-vaccination) and Cohort 2: up to Day 387 (post-vaccination)

No measurements were reported for this outcome.

SecondaryNumber of Participants With Serologically-confirmed SARS-CoV-2 Infection

Serologically-confirmed SARS-CoV-2 infection as defined by SARS-CoV-2 Nucleoprotein specific antibody detection immunoassay was reported in this outcome measure.

Time frame:
Cohort 1: up to Day 366 (post-vaccination) and Cohort 2: up to Day 387 (post-vaccination)

No measurements were reported for this outcome.

SecondaryCorrelates of Risk/Protection Based on Antibody Responses to SARS-CoV-2

Correlate of risk / protection based on antibody responses to SARS-CoV-2 was evaluated using virus neutralization or ELISA, considering virologically-confirmed COVID-19-like illness and/or serologically-confirmed SARS-CoV-2 infection.

Time frame:
Cohort 1: up to Day 366 (post-vaccination) and Cohort 2: up to Day 387 (post-vaccination)

No measurements were reported for this outcome.

Adverse events

Collected over Unsolicited AEs were collected within 21 days post-vaccination. Solicited reaction data were collected within 7 days post any vaccination. SAE data were collected from Day 1 up to 12 months post last vaccination (i.e., up to Day 366 for Cohort 1 groups and up to Day 387 for Cohort 2 groups). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1: SARS-CoV-2 Vaccine Ultra Low Dose0/37 (0%)0/37 (0%)31/37 (83.8%)
Cohort 1: SARS-CoV-2 Vaccine Low Dose0/34 (0%)0/34 (0%)30/34 (88.2%)
Cohort 1: Placebo0/18 (0%)1/18 (5.6%)11/18 (61.1%)
Cohort 2: SARS-CoV-2 Vaccine Ultra Low Dose0/36 (0%)0/36 (0%)34/36 (94.4%)
Cohort 2: SARS-CoV-2 Vaccine Low Dose0/36 (0%)0/36 (0%)35/36 (97.2%)
Cohort 2: SARS-CoV-2 Vaccine Medium Dose0/10 (0%)1/10 (10%)10/10 (100%)
Cohort 2: Placebo0/9 (0%)0/9 (0%)7/9 (77.8%)
Most frequent serious events
Most frequent serious events
EventCohort 1: SARS-CoV-2 Vaccine Ultra Low DoseCohort 1: SARS-CoV-2 Vaccine Low DoseCohort 1: PlaceboCohort 2: SARS-CoV-2 Vaccine Ultra Low DoseCohort 2: SARS-CoV-2 Vaccine Low DoseCohort 2: SARS-CoV-2 Vaccine Medium DoseCohort 2: Placebo
Cystitis HaemorrhagicRenal and urinary disorders0/370/340/180/360/361/100/9
Covid-19Infections and infestations0/370/341/180/360/360/100/9
Most frequent other events
Showing 10 of 36
Most frequent other events
EventCohort 1: SARS-CoV-2 Vaccine Ultra Low DoseCohort 1: SARS-CoV-2 Vaccine Low DoseCohort 1: PlaceboCohort 2: SARS-CoV-2 Vaccine Ultra Low DoseCohort 2: SARS-CoV-2 Vaccine Low DoseCohort 2: SARS-CoV-2 Vaccine Medium DoseCohort 2: Placebo
Injection Site PainGeneral disorders28/3728/345/1833/3633/3610/102/9
MalaiseGeneral disorders21/3721/345/1828/3631/3610/102/9
PyrexiaGeneral disorders5/378/341/1810/3616/3610/100/9
ArthralgiaMusculoskeletal and connective tissue disorders7/3713/342/1820/3623/3610/102/9
HeadacheNervous system disorders18/3718/347/1826/3631/3610/105/9
ChillsGeneral disorders14/3717/344/1820/3629/369/101/9
MyalgiaMusculoskeletal and connective tissue disorders20/3723/344/1828/3628/368/102/9
DiarrhoeaGastrointestinal disorders1/372/340/180/361/362/101/9
Injection Site SwellingGeneral disorders1/372/340/186/364/362/100/9
Injection Site ErythemaGeneral disorders2/370/340/184/365/360/100/9

Baseline characteristics

Analysis was performed on all enrolled participants according to the intervention to which they were randomized. Data for baseline characteristics was planned to be collected and analyzed for combined population (Full Enrollment Cohort + Sentinel Cohort) in which the same dose-level groups in Sentinel Cohort and Full Enrollment Cohort were pooled for the analysis. Since Sentinel Cohort: SARS-CoV-2 Vaccine Medium Dose group received 2 injections; they were presented under Cohort 2 for analysis.

Age, Continuous
Age, Continuous(years)Cohort 1: SARS-CoV-2 Vaccine Ultra Low DoseCohort 1: SARS-CoV-2 Vaccine Low DoseCohort 1: PlaceboCohort 2: SARS-CoV-2 Vaccine Ultra Low DoseCohort 2: SARS-CoV-2 Vaccine Low DoseCohort 2: SARS-CoV-2 Vaccine Medium DoseCohort 2: PlaceboTotal
Mean44.15 ± 16.1941.96 ± 17.0539.77 ± 14.9636.21 ± 13.0034.96 ± 13.2231.00 ± 8.9438.79 ± 16.2438.01 ± 14.68
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1: SARS-CoV-2 Vaccine Ultra Low DoseCohort 1: SARS-CoV-2 Vaccine Low DoseCohort 1: PlaceboCohort 2: SARS-CoV-2 Vaccine Ultra Low DoseCohort 2: SARS-CoV-2 Vaccine Low DoseCohort 2: SARS-CoV-2 Vaccine Medium DoseCohort 2: PlaceboTotal
Female1010518253677
Male17168202978105
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort 1: SARS-CoV-2 Vaccine Ultra Low DoseCohort 1: SARS-CoV-2 Vaccine Low DoseCohort 1: PlaceboCohort 2: SARS-CoV-2 Vaccine Ultra Low DoseCohort 2: SARS-CoV-2 Vaccine Low DoseCohort 2: SARS-CoV-2 Vaccine Medium DoseCohort 2: PlaceboTotal
American Indian or Alaska Native55312710345
Asian00002002
Native Hawaiian or Other Pacific Islander01002003
Black or African American020280416
White221810243405113
More than one race00001012
Unknown or Not Reported00000011
08

Study locations

21 sites
  • Investigational Site Number :8400003
    Rolling Hills Estates, California 90274, United States
  • Investigational Site Number :8400002
    Hollywood, Florida 33024, United States
  • Investigational Site Number :8400006
    Miami, Florida 33135, United States
  • Investigational Site Number :8400017
    Iowa City, Iowa 52242, United States
  • Investigational Site Number :8400007
    Kansas City, Missouri 64114, United States
  • Investigational Site Number :8400008
    Omaha, Nebraska 68134, United States
  • Investigational Site Number :8400001
    Rochester, New York 14609, United States
  • Investigational Site Number :8400010
    Philadelphia, Pennsylvania 19104, United States
  • Investigational Site Number :8400004
    North Charleston, South Carolina 29405, United States
  • Investigational Site Number :8400015
    Knoxville, Tennessee 37920, United States
  • Investigational Site Number :8400009
    Houston, Texas 77081, United States
  • Investigational Site Number :8400005
    Salt Lake City, Utah 84107, United States
  • Investigational Site Number :0360003
    Morayfield, Queensland 4506, Australia
  • Investigational Site Number :0360005
    South Brisbane, Queensland 4101, Australia
  • Investigational Site Number :0360001
    Melbourne, Victoria 3010, Australia
  • Investigational Site Number :0360002
    Nedlands, Western Australia 6009, Australia
  • Investigational Site Number :0760001
    Salvador, Estado de Bahia 40415-006, Brazil
  • Investigational Site Number :0760004
    Campo Grande, Mato Grosso do Sul 79070-900, Brazil
  • Investigational Site Number :0760003
    Belo Horizonte, Minas Gerais 30110-063, Brazil
  • Investigational Site Number :3400002
    Barrio del Centro, 11101, Honduras
  • Investigational Site Number :3400001
    San Pedro Sula, 21104, Honduras
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2021 to primary completion in Jun 2022, 15 months.

Results were first posted in Dec 2023, 1 year 5 months after primary completion. A results delay was requested in Jun 2023.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 11, 2021
First posted
Mar 15, 2021
StartActual
Mar 12, 2021
Primary completionActual
Jun 27, 2022
CompletionActual
Jun 27, 2022
Results delay requested
Jun 21, 2023
Results first posted
Dec 15, 2023
Last update
Sep 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04798027
Responsible party
Sponsor
First posted
Mar 15, 2021
Start date
Mar 12, 2021
Primary completion
Jun 27, 2022
Completion
Jun 27, 2022
Results posted
Dec 15, 2023
Last update
Sep 11, 2025

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion